Research and Training Funding

Funding Opportunity Announcements

Browse below for Data Science Funding Opportunity Announcements.

This page last reviewed on August 7, 2019

Feed last updated: August 04 2020 8:46 pm
Title FOA Number Organization Release Date Expiration Date Purpose Search Terms
Institutional Training Programs to Advance Translational Research on Alzheimer's Disease and AD Related Dementias (T32 - Clinical Trial Not Allowed) PAR-18-524 NIA Dec 21 2017 Jan 08 2021 This Funding Opportunity Announcement (FOA) seeks to enable the development of a diverse, translational research workforce capable of participating and/or leading cross-disciplinary team science programs focused on advancing therapy development for Alzheimer's disease (AD) and AD-related dementias. This FOA will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e. basic biology, translational and clinical research, data science). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational and clinical research for AD and AD-related dementias. data science
Institutional Training for a Dental, Oral and Craniofacial Research Workforce (T90/R90 Clinical Trial Not Allowed) PAR-20-056 NIDCR Nov 20 2019 Sep 27 2022 The National Institute of Dental and Craniofacial Research (NIDCR) will award T90/R90 grants to eligible, domestic institutions to enhance predoctoral and postdoctoral research training (T90) and postdoctoral research education (R90) to ensure that a diverse and highly qualified workforce is available to address the Nations basic and clinical biomedical and behavioral or social sciences research agenda. Research training programs will incorporate didactic, research, and career development components to prepare individuals for careers as independent scientists that will have a significant impact on the dental, oral, and craniofacial health-related research needs of the Nation. This Funding Opportunity Announcement (FOA) does not allow appointed trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.
Initiative to Maximize Research Education in Genomics: Diversity Action Plan (R25) PAR-19-380 NHGRI Sep 17 2019 Sep 26 2022 The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that The overarching goal of this NHGRI R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce in genomics. This funding opportunity announcement seeks to expose underrepresented students at the undergraduate, post-baccalaureate and graduate levels to the foundational sciences relevant to genomics to enable them to pursue careers that span all areas of interest to NHGRI - genome sciences, genomic medicine and genomics and society. For the purposes of this FOA, the term genomics encompasses issues and activities in these three areas of genomic research.
High impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional) PAR-19-202 NIDDK Feb 27 2019 Nov 03 2021 The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment and prevention of diseases within the mission of NIDDK.
HHS Small Business Innovation Research (SBIR) Program Contract Solicitation (PHS 2020-1) Now Available NOT-OD-19-121 NIH Jul 10 2019 N/A HHS Small Business Innovation Research SBIR) Program Contract Solicitation PHS 2020-1) Available Notice Number: NOT-OD-19-121 Key Dates Release Date: July 10, 2019 Related Announcements None Issued National Institutes Health NIH) Centers Disease Control Prevention CDC) Purpose Innovative technologies methodologies fuel progress biomedical behavioral research represent increasingly important area the economy. Small Business Innovation Research SBIR) program provides support research development R&D) new improved technologies methodologies have potential succeed commercial products.   purpose this notice to 1) announce issuance the Solicitation the National Institutes Health the Centers Disease Control Prevention Small Business Innovation Research Contract Proposals PHS 2020-1) a receipt date October 23, 2019, 5:00PM EDT; 2) inform public the opportunities the SBIR program offers small business concerns well to scientists research institutions. SBIR legislation requires Public Health Service PHS), Department Health Human Services, certain Federal agencies reserve 3.2 percent FY 2019) their extramural research R&D budgets an SBIR program. NIH SBIR set-aside requirement FY 2019 1 billion.) offeror organization must a small business concern defined the Small Business Administration described the Contract Solicitation. primary employment the principal investigator MUST with small business concern the time award during conduct the proposed project. accord the intent the SBIR program increase private sector commercialization innovations derived Federal R&D, scientists research institutions play important role an SBIR project serving consultants and/or subcontractors the small business concern. Generally, to 1/3 the Phase budget be spent consultant and/or subcontractual costs, and, generally, to 1/2 the Phase II budget be spent such costs. this manner, small business concern limited expertise and/or research facilities benefit teaming a scientist(s) a research institution; the scientist(s) a research institution, team effort provides support R&D otherwise obtained. SBIR program consists the following three phases: PHASE I: objective this phase to determine scientific technical merit feasibility potential commercialization the proposed research R&D efforts the quality performance the small business concern, before consideration further Federal support Phase II. Generally, Phase SBIR awards not exceed 150,000 direct costs, Facilities Administrative F&A) costs, negotiated fixed fee a period generally to exceed six months. PHASE II: objective this phase to continue research R&D efforts initiated Phase I. Funding shall based the results Phase and scientific technical merit commercial potential the Phase II proposal. Phase contractors eligible apply Phase II grant contract funding will informed Phase II opportunities. However, Fast-Track" Initiative Direct Phase II" below.) Generally, Phase II awards not exceed 1,000,000 direct costs, F&A costs, negotiated fixed fee a period generally to exceed years. PHASE III: objective this phase for small business concern pursue, non-SBIR funds, commercialization the results the research R&D funded Phases and II. FAST-TRACK": Applicable only proposals submitted the NIH only an awarding component indicates it accepting Fast-Track proposals a particular topic.) Fast-Track initiative an opportunity small business concerns submit both Phase and Phase II proposal concurrent peer review. initiative also the potential minimize any funding gap between Phase and Phase II. Proposals must prepared accordance Phase and Phase II proposal preparation instructions. DIRECT PHASE II: Applicable only proposals submitted the NIH only an awarding component indicates it accepting Direct Phase II proposals a particular topic.) SBIR Direct Phase II a pilot authority under P.L. 112-81 allows NIH issue Phase II award a small business concern did receive Phase award that research/research & development.  Certain NIH topics allow Direct Phase II SBIR proposals this solicitation.  Proposals must prepared accordance the Phase II proposal preparation instructions. Submission Process: Offerors responsible submitting proposals, including any revisions modifications the electronic Contract Proposal Submission eCPS) website https://ecps.nih.gov/sbirsttr the deadline.  Offerers must this electronic transmission method.  other method proposal submission permitted.  Instructions electronic submission provided the solicitation. Pre-proposal webinar: HHS hold pre-proposal conference, via webinar, August 7, 2019 1:00 PM Eastern Daylight Time.  informational webinar discuss PHS 2020-1 solicitation, in particular discuss electronic contract proposal submission eCPS) website.  this solicitation, proposals only accepted via eCPS website. Offerors register the webinar at: HHS SBIR PHS 2020-1 Contract Webinar Please register HHS SBIR PHS 2020-1 Contract Webinar Aug 7, 2019 1:00 PM EDT at:  https://attendee.gotowebinar.com/register/7505039171902241027 After registering, will receive confirmation email containing information joining webinar. Following registration, confirmation e-mail be sent containing information joining webinar. Presentation material this webinar shall posted FedBizOpps the NIH SBIR/STTR webpage following completion. Following the research topics contained the PHS 2020-1 Solicitation: National Institutes Health NIH) National Center Advancing Translational Sciences NCATS) 019       Alternatives commercially available cell culture insert membranes manufacturing techniques National Cancer Institute NCI) 397       Manufacturing Innovation the Production Cell-Based Cancer Immunotherapies 398       Development Senolytic Agents Cancer Treatment 399       Combinatory Treatment Utilizing Radiation Locally Activate Systemically Delivered Therapeutics 400       Sensing Tools Measure Biological Response Radiotherapy 401       Quantitative Biomimetic Phantoms Cancer Imaging 402       Artificial Intelligence-Aided Imaging Cancer Prevention, Diagnosis, Monitoring 403       Spatial Sequencing Technologies Single Cell Resolution Cancer Research 404       Subcellular Microscopy Omics Cancer Cell Biology 405       Intra-Tumor Sensing Technologies Tumor Pharmacotyping 406       Software Patient Navigation Through Cancer Care Continuum 407       Cloud-Based Software the Cancer Research Data Commons 408       Tools Technologies Visualizing Multi-Scale Data 409       Software Automated Analysis Images Improved Cancer Health 410       Cancer Clinical Trials Recruitment Retention Tools Participant Engagement 411       De-Identification Software Tools Cancer Imaging Research 412       Software Enabling Data Integration Wearable Sensors Cancer Patients National Heart, Lung Blood Institute NHLBI) 109       Transcatheter trileaflet tricuspid suture repair system 110       MRI myocardial biopsy system National Institute Alcohol Abuse Alcoholism NIAAA) 018       Alcohol Biosensor Development Continuous Alcohol Consumption Monitoring 019       Data Science Tools Accelerating Alcohol Research National Institute Allergy Infectious Diseases NIAID) 076       Co-delivery Formulation Adjuvants HIV Vaccine Development 077       Particle-based Co-delivery HIV immunogens Next-generation HIV Vaccines 078       Sequence-based Assays Quantify Replication-Competent HIV Reservoir 079       Small Molecule Targeting HIV RNA 080       Adjuvant Discovery Vaccines against Infectious Immune-mediated Diseases 081       Adjuvant Development Vaccines against Infectious Immune-mediated Diseases 082       Production Adjuvants 083       Reagents Immunologic Analysis Non-mammalian Underrepresented Mammalian Models 084       Antiviral drugs cure chronic hepatitis B virus infection 085       Broad spectrum antibody against human enteroviruses 086       Development rapid fungal diagnostics select endemic dimorphic fungi Centers Disease Control Prevention CDC) National Center Chronic Disease Health Promotion NCCDPHP) 043       Objective Measurement Opioid Withdrawal Newborns National Center Environmental Health NCEH) 02         Web-Based Platform Flooding Vulnerability HealthCare Access National Center Emerging Zoonotic Infectious Diseases NCEZID) 021       Assay Detect Quantify E. Coli O157 Water Samples 022       Device Development Microbial Surface Sampling Field Extraction Collection 023       Diagnostic Testing Platform Assess Antibiotic Communities Cystic Fibrosis Patients National Center Immunization Respiratory Diseases NCIRD) 034       Accelerating Time Detection Legionella Environmental Samples Inquiries Please direct inquiries to: Eligibility requirements, definitions, submission procedures, review considerations, contract proposal forms instructions, other pertinent information, including Fast-Track" Initiative, contained the Solicitation PHS 2020-1). Solicitation, including contract proposal forms, available electronically through NIH Small Business Research Funding Opportunities” Web site. SBIR Phase Contract Solicitation PHS 2020-1 PDF http://grants.nih.gov/grants/funding/SBIRContract/PHS2020-1.pdf] MS http://grants.nih.gov/grants/funding/SBIRContract/PHS2020-1.docx]). sure use appropriate CONTRACT PROPOSAL forms they differ the SF424 R&R) GRANT application forms. Note: SBIR Contract Solicitation available ONLY via electronic means. Potential offerors encouraged check NIH Small Business Research Funding Opportunities Web site updates the program. Any updates corrections the Solicitation be posted there. Contracting Officers Any small business concern intends submit SBIR contract proposal under Solicitation should provide appropriate contracting officer(s) early, written notice its intent, giving name, address, e-mail, telephone, topic number(s). a topic modified canceled before Solicitation closes, only those companies have expressed such intent be notified. National Institutes Health NIH) National Center Advancing Translational Sciences NCATS) Jessica Adams Contracting Officer NIDA Office Acquisition Email: jessica.adams@nih.gov National Cancer Institute NCI) Brittany Gibau Contracts Analyst Office Acquisitions, OM, NCI Contractor) Telephone: 240) 276-6863 Email: ncioasbir@mail.nih.gov National Heart, Lung, Blood Institute NHLBI) Kristi Cooper Office Acquistions, OM, NHLBI Telephone: 301-827-7704 Email: kristi.cooper@nih.gov National Institute Alcohol Abuse Alcoholism NIAAA) Jeremy White Contracting Officer Branch Chief, NIAAA Branch NICHD Office Acquisitions National Institutes Health, DHHS Telephone: 301-402-4572 Email: jeremy.white@nih.gov  National Institute Allergy Infectious Diseases NIAID) Charles H. Jackson, Jr. Contracting Officer Office Acquisitions, DEA, NIAID Telephone: 240-669-5175 Email: Charles.Jackson@.nih.gov Centers Disease Control Prevention CDC) general administrative SBIR program questions, contact: Sean David Griffiths, M.P.H. SBIR Program Manager Office Technology Innovation Office Science Telephone: 404-639-4641 Fax: 404-639-4903 Email:  SBIR@cdc.gov Miriam Kelly, Ph.D. Office Technology Innovation Office Science Telephone: 404-639-4784 Fax: 404-639-4903 Email: SBIR@cdc.gov National Center Chronic Disease Health Promotion NCCDPHP) Jerry Outley Contracting Officer Centers Disease Control Prevention Office Financial Resources Telephone: 770-488-2831 Fax: 770-488-2044 Email: Jmo4@cdc.gov National Center Emerging Zoonotic Infectious Diseases NCEZID) Priscilla Turner Contracting Officer Centers Disease Control Prevention Office Financial Resources Telephone: 770-488-2821 Fax: 770-488-2024 Email:  PBTurner@cdc.gov National Center Environmental Health NCEH) Dale Bish Contracting Officer Centers Disease Control Prevention Office Financial Resources Telephone: 404-498-1312 Fax: 770-488-2847 Email:  uwo8@cdc.gov   National Center Immunization Respiratory Diseases NCIRD) Pellumbeshe Hoxhaj Contracting Officer Centers Disease Control Prevention Office Financial Resources Office Acquisition Services Telephone: 770-488-2805 Fax: 770-488-2847 Email:  KFX2@CDC.gov Those interested the PHS small business research GRANT programs, where investigator-initiated research ideas encouraged, invited access Omnibus Solicitation the Public Health Service Small Business Innovation Research SBIR) Small Business Technology Transfer STTR) Grant Applications PHS 2019-2). understand better differences between grants contracts, https://sbir.nih.gov/apply.   data science, data integration, artificial intelligence
HHS Small Business Innovation Research (SBIR) Program Contract Solicitation (PHS 2019-1) Now Available NOT-OD-18-209 NIH Jul 18 2018 N/A HHS Small Business Innovation Research SBIR) Program Contract Solicitation PHS 2019-1) Available Notice Number: NOT-OD-18-209 Key Dates Release Date: July 18, 2018 Related Announcements None Issued National Institutes Health NIH) Centers Disease Control Prevention CDC) Purpose Innovative technologies methodologies fuel progress biomedical behavioral research represent increasingly important area the economy. Small Business Innovation Research SBIR) program provides support research development R&D) new improved technologies methodologies have potential succeed commercial products. purpose this notice to 1) announce issuance the Solicitation the National Institutes Health the Centers Disease Control Prevention Small Business Innovation Research Contract Proposals PHS 2019-1) a receipt date October 22, 2018, 5:00PM EDT; 2) inform public the opportunities the SBIR program offers small business concerns well to scientists research institutions. SBIR legislation requires Public Health Service PHS), Department Health Human Services, certain Federal agencies reserve 3.2 percent FY 2018) their extramural research R&D budgets an SBIR program. NIH SBIR set-aside requirement FY 2018 941 million.) offeror organization must a small business concern defined the Small Business Administration described the Contract Solicitation. primary employment the principal investigator MUST with small business concern the time award during conduct the proposed project. accord the intent the SBIR program increase private sector commercialization innovations derived Federal R&D, scientists research institutions play important role an SBIR project serving consultants and/or subcontractors the small business concern. Generally, to 1/3 the Phase budget be spent consultant and/or subcontractual costs, and, generally, to 1/2 the Phase II budget be spent such costs. this manner, small business concern limited expertise and/or research facilities benefit teaming a scientist(s) a research institution; the scientist(s) a research institution, team effort provides support R&D otherwise obtained. SBIR program consists the following three phases: PHASE I: The objective this phase to determine scientific technical merit feasibility potential commercialization the proposed research R&D efforts the quality performance the small business concern, before consideration further Federal support Phase II. Generally, Phase SBIR awards not exceed 150,000 direct costs, Facilities Administrative F&A) costs, negotiated fixed fee a period generally to exceed six months. PHASE II: The objective this phase to continue research R&D efforts initiated Phase I. Funding shall based the results Phase and scientific technical merit commercial potential the Phase II proposal. Phase contractors eligible apply Phase II grant contract funding will informed Phase II opportunities. However, Fast-Track" Initiative Direct Phase II" below.) Generally, Phase II awards not exceed 1,000,000 direct costs, F&A costs, negotiated fixed fee a period generally to exceed years. PHASE III: The objective this phase for small business concern pursue, non-SBIR funds, commercialization the results the research R&D funded Phases and II. FAST-TRACK": (Applicable only proposals submitted the NIH only an awarding component indicates it accepting Fast-Track proposals a particular topic.) Fast-Track initiative an opportunity small business concerns submit both Phase and Phase II proposal concurrent peer review. initiative also the potential minimize any funding gap between Phase and Phase II. Proposals must prepared accordance Phase and Phase II proposal preparation instructions. DIRECT PHASE II: The congressional authority SBIR Direct Phase II expired.  Accordingly Direct Phase II proposals WILL NOT be accepted this soliciation. Submission Process: Offerors responsible submitting proposals, including any revisions modifications the electronic Contract Proposal Submission eCPS) website at https://ecps.nih.gov/sbirsttr by deadline.  Offerers must this electronic transmission method.  other method proposal submission permitted.  Instructions electronic submission provided the solicitation. Pre-proposal webinar: HHS hold pre-proposal conference, via webinar, August 16, 2018 2:00 PM Eastern Daylight Time.  informational webinar discuss PHS 2019-1 solicitation, in particular discuss new electronic contract proposal submission eCPS) website.  this solicitation, proposals only accepted via eCPS website. Offerors register the webinar at: HHS SBIR PHS 2019-1 Contract Webinar Please register for HHS SBIR PHS 2019-1 Contract Webinar on Aug 16, 2018 2:00 PM EDT at:  https://attendee.gotowebinar.com/register/4384275519409493762 After registering, will receive confirmation email containing information joining webinar. Following registration, confirmation e-mail be sent containing information joining webinar. Presentation material this webinar shall posted FedBizOpps the NIH SBIR/STTR webpage following completion. Following the research topics contained the PHS 2019-1 Solicitation: National Institutes Health NIH) National Center Advancing Translational Sciences NCATS) 016 Synthetic Technologies Advancement Research Therapeutics START) 017 Universal Medium/Blood Mimetic Use Integrated Organs-on-Chips 018 Non-PDMS Biocompatible Alternatives Organs-On-Chips National Cancer Institute NCI) 382 Integrated Subcellular Microscopy Omics Cancer Cell Biology 383 Smart, Multi-Core Biopsy Needle 384 Digital Healthcare Platform Reduce Financial Hardship Cancer Patients 385 Leveraging Connected Health Technologies Address Improve Health Outcomes Long Term Cancer Survivors 386 Novel Approaches Local Delivery Chemopreventive Agents 387 Multiplexed Preclinical Tools Longitudinal Characterization Immunological Status Tumor its Microenvironment 388 vitro Diagnostic the Liver Flukes Opisthorchis viverrini Clonorchis sinensis 389 Development Artificial Intelligence AI) Tools Understand Duplicate Experts’ Radiation Therapy Planning Prostate Cancer 390 Clonogenic High-Throughput Assay Screening Anti-Cancer Agents Radiation Modulators 391 Drugs Devices Exploit Immune Response Generated Radiation Therapy 392 Clinical Trials Systemic Targeted Radionuclide Therapies 393 Sensing Tools Measure Biological Response Radiotherapy 394 Combinatory Treatment Modalities Utilizing Radiation Locally Activate Release Systemically Delivered Therapeutics 395 Targeted Therapy Cancer- Cancer Therapy-Related Cachexia 396 Imaging Cancer Immunotherapies National Heart, Lung Blood Institute NHLBI) 106 Active MRI Needle 107 Transcatheter Potts Shunt 108 Device System Transcatheter Repair Postinfarction Ventricular Septal Defect National Institute Alcohol Abuse Alcoholism NIAAA)) 016 Wearable Alcohol Biosensor Quantifies Blood Alcohol Concentration Real Time 017 Data Science Tools Alcohol Research National Institute Allergy Infectious Diseases NIAID) 063 Vivo Targeted Degradation HIV Proteins 064 Particle-Based Delivery HIV Env Immunogens 065 Co-Delivery Formulation Adjuvants HIV Vaccines 066 Effective Targeted Delivery RNA-based Vaccines Therapeutics 067 Methods Improving HIV Protein Expression: Cell Substrate Protein Purification 068 Reagents Immunologic Analysis Non-mammalian Underrepresented Mammalian Models 069 B Cell Receptor T Cell Receptor Repertoire Computational Tools 070 Development Sample Sparing Assay 071 Adjuvant Discovery Vaccines for Autoimmune Allergic Diseases 072 Adjuvant Development Vaccines for Autoimmune Allergic Diseases 073 Mobile Health Point-of-Care Diagnostics 074 Development POC Assays Quantify anti-Tuberculosis Antibiotics Blood 075 POC Diagnostic Gonorrhea Determination Antimicrobial Susceptibility National Institute Drug Abuse NIDA) 165 DEA-Compliant Drug Detection Deactivation Technology Deter Opioid Theft Hospitals Next Generation Controlled Substance Diversion Prevention Program CSDPP) 166 Leveraging Health Solutions Combat Opioid Misuse Centers Disease Control Prevention CDC) Center Global Health CGH) 010 Multiplex Detection Recent Prior Exposure Pathogens 011 Preservation Supply Quality During Unmanned Aerial Vehicle UAV) Transport National Center Chronic Disease Health Promotion NCCDPHP) 041 Community Based Worksite Wellness App Linking Employees Wellness Resources 042 Objective Measurement Opioid Withdrawal Newborns National Center Emerging Zoonotic Infectious Diseases NCEZID) 020 Novel Coatings/Surfaces Indwelling Medical Devices Prevent Biofilms National Center Environmental Health NCEH) 01 Rapid Field Test Improve Swimming Pool Water/Air Quality Office Public Health Preparedness Response OPHPR) 03 Rapid Test Simultaneous Detection Influenza types and B) Streptococcus Group A) Inquiries Please direct inquiries to: Eligibility requirements, definitions, submission procedures, review considerations, contract proposal forms instructions, other pertinent information, including Fast-Track" Initiative, contained the Solicitation PHS 2019-1). Solicitation, including contract proposal forms, available electronically through NIH Small Business Research Funding Opportunities” Web site. SBIR Phase Contract Solicitation PHS 2019-1 PDF http://grants.nih.gov/grants/funding/SBIRContract/PHS2019-1.pdf] MS http://grants.nih.gov/grants/funding/SBIRContract/PHS2019-1.docx]). sure use appropriate CONTRACT PROPOSAL forms they differ the SF424 R&R) GRANT application forms. Note: SBIR Contract Solicitation available ONLY via electronic means. Potential offerors encouraged check the NIH Small Business Research Funding Opportunities Web site updates the program. Any updates corrections the Solicitation be posted there. Contracting Officers Any small business concern intends submit SBIR contract proposal under Solicitation should provide appropriate contracting officer(s) early, written notice its intent, giving name, address, e-mail, telephone, topic number(s). a topic modified canceled before Solicitation closes, only those companies have expressed such intent be notified. National Institutes Health NIH) National Center Advancing Translational Sciences NCATS) Jeffrey Schmidt Contracting Officer NIDA Office Acquisition Phone: 301) 402-1488 Email: schmidtjr@mail.nih.gov National Cancer Institute NCI) Tiffany Chadwick Procurement Analyst & Contract Officer Office Acquisitions National Cancer Institute Phone: 240-276-7293 E-mail: ncioasbir@mail.nih.gov National Heart, Lung, Blood Institute NHLBI) Joanna Magginas Deputy Director, OA, OM, NHLBI Phone: 301) 827-7740 E-mail: magginaj@nhlbi.nih.gov National Institute Alcohol Abuse Alcoholism NIAAA) Jeremy White Contracting Officer Branch Chief, NIAAA Branch NICHD Office Acquisitions National Institutes Health, DHHS Phone: 301) 402-4572 Email: jeremy.white@nih.gov National Institute Allergy Infectious Diseases NIAID) Charles H. Jackson, Jr. Team Lead, Microbiology Infectious Diseases Research Contracts Branch-A MIDRCB-A) Office Acquisitions, DEA, NIAID Phone: 240) 669-5175 Email: Charles.Jackson@.nih.gov National Institute Drug Abuse NIDA) Kenneth Janosko Contracting Officer Office Acquisition, NIDA Phone: 301) 443-6677 Fax: 301) 443-7595 E-mail: kenneth.janosko@nih.gov Centers Disease Control Prevention CDC) general administrative SBIR program questions, contact: Sean David Griffiths, M.P.H. Office Technology Innovation Office the Associate Director Science Phone: 404-639-4641 Fax: 404-639-4903 E-mail:  SBIR@cdc.gov Gwen Barnett, M.P.H. Deputy Director Office Technology Innovation Office the Associate Director Science Phone: 404-639-4791 Fax: 404-639-4903 Email: SBIR@cdc.gov Center Global Health CGH) Theresa Routh-Murphy Contracting Officer Centers Disease Control Prevention Office Financial Resources Phone: 770) 488-2713 Fax: 770) 488-2778 Email: TRouthMurphy@cdc.gov National Center Chronic Disease Health Promotion NCCDPHP) Julio Lopez Contracting Officer Centers Disease Control Prevention Office Financial Resources Phone: 770) 488-2892 Fax: 770) 488-2044 E-mail:  JLopez3@cdc.gov   National Center Emerging Zoonotic Infectious Diseases NCEZID) Priscilla Turner Contracting Officer Centers Disease Control Prevention Office Financial Resources Phone: 770) 488-2821 Fax: 770) 488-2024 E-mail:  PBTurner@cdc.gov National Center Environmental Health NCEH) Vallerie Redd Contracting Officer Center Disease Control Prevention Office Financial Resources Phone: 770) 488-2845 Fax: 770) 488-2847 E-mail:  GFJ3@cdc.gov   Office Public Health Preparedness Response OPHPR) Christine Godfrey Contracting Officer Centers Disease Control Prevention Office Financial Resources Phone: 770) 488-2519 Fax: 770) 488-2024 E-mail:  CNP9@cdc.gov Those interested the PHS small business research GRANT programs, where investigator-initiated research ideas encouraged, invited access the Omnibus Solicitation the Public Health Service Small Business Innovation Research SBIR) Small Business Technology Transfer STTR) Grant Applications PHS 2018-2). understand better differences between grants contracts, see https://sbir.nih.gov/apply. data science, computational, artificial intelligence
Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional) PAR-18-764 NIAID Apr 20 2018 May 08 2021 The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles. data science, big data
Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional) PAR-20-036 NIAID Oct 24 2019 Sep 08 2022 The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology, novel tools from data science approaches and m/eHealth, and implementation science research. Data generated through this research will be used to inform and evaluate context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.
Fast Healthcare Interoperability Resources (FHIR) Standard NOT-OD-19-122 NIH Jul 30 2019 N/A Fast Healthcare Interoperability Resources FHIR®) Standard Notice Number: NOT-OD-19-122 Key Dates Release Date: July 30, 2019 Related Announcements NOT-OD-19-014 NOT-OD-18-134 NOT-OD-19-150 Issued OFFICE THE DIRECTOR, NATIONAL INSTITUTES HEALTH OD) Purpose purpose this notice to encourage NIH researchers explore use the Fast Healthcare Interoperability Resources FHIR®) standard capture, integrate, exchange clinical data research purposes to enhance capabilities share research data. Background Once research approved compliant human subjects protections, FHIR format accelerate use clinical data research. FHIR a standardized of transmitting health data one health information system another through application programming interface API). is being widely promoted adopted use clinical care. addition, FHIR provides way structure data generated research a manner protects patient privacy fosters interoperability interchange both research clinical data. FHIR benefits relative ease implementation, availability open source implementation tools, considerable industry support, an American National Standards Institute consensus development process. is also compatible analytic resources used biomedical research, such R Python. Several Federal health agencies promoting use FHIR electronic health record EHR) systems. 21st Century Cures Act requires a health information technology developer entity allow health information…to accessed, exchanged, used without special effort through use application programming interfaces APIs)… including providing access all data elements a patient's electronic health record.”[1] To implement provision, Department Health Human Services, Office the National Coordinator Health Information Technology ONC) proposed new rule support seamless secure access, exchange, use electronic health information.[2]Specifically, proposed rule calls the health care industry adopt standardized APIs using FHIR standard share patient data. Concurrently, Centers Medicare & Medicaid Services CMS) released proposed rule requirements Medicaid, Children’s Health Insurance Program, Medicare Advantage plans, Qualified Health Plans the federally facilitated exchanges provide enrollees immediate electronic access medical claims other health information electronically 2020 adopting implementing openly published APIs.[3] CMS also require health care providers plans implement open data sharing technologies are consistent the FHIR standard ONC’s notice proposed rulemaking NPRM). Both NPRMs also support use specific content vocabulary standards achieve interoperability. FHIR broadly used health care. of mid-April 2019, approximately third developers certified under 2015 Edition[4] of ONC’s Health Information Technology IT) Certification Program published they using FHIR API.[5] It estimated approximately 96% hospitals 74% clinicians EHR systems some FHIR API capabilities. addition, federal agencies using FHIR exchange data. example, CMS developed Blue Button 2.0 FHIR API enable exchange claims data software applications.[6] Payors, including CMS, providers working together automate data sharing using FHIR under Da Vinci Project.[7] The broader sector also begun adopting FHIR, example, enable individuals import health records providers’ EHR systems to support uploading data cloud-based services. Pharmaceutical companies also active FHIR development efforts,[8] including use FHIR integrate clinical trial management EHRs.[9] FHIR framework accelerate research uses data collected the course clinical care. example, while monitoring cardiovascular, renal, kidney function during experimental evaluation a new therapeutic, query process be established using FHIR framework provide instructions access authorized participant’s electronic health record, extract medication list, vital signs laboratory observations, then transmit information directly a clinical trial management systems other research data repository. respective interoperability goals the NPRMs issued ONC CMS align and facilitate of objectives asserted the NIH Strategic Plan Data Science,[10] as well NIH’s long-term policy goals data management sharing.[11] Additionally, National Library Medicine, its Strategic Plan, 2017-2027,[12] proposes technical scientific advances ensure research data Findable, Accessible, Interoperable Re-usable FAIR) while protecting patient privacy security.[13] number tools technical resources supporting use FHIR clinical care administrative purposes already exist. addition, NIH considering approaches foster development FHIR tools support research uses clinical administrative data. NIH plans issue Request Information solicit input the scientific community other stakeholders the types tools might needed support of FHIR biomedical research, well implementation challenges opportunities foresee using FHIR, including privacy, security, protection patient data. Through notice, NIH encourages funded researchers explore use the FHIR standard capture integrate patient- population-level data clinical information systems research purposes to it common structure sharing research data. with NIH-funded supported research involving human participants, as currently expectation using FHIR, investigators must obtain participant consents follow applicable national, tribal, state laws regulations, well relevant institutional policies, the protection human subjects. about FHIR Health Level Seven International HL7®) FHIR a standardized of transmitting health data one health information system another through API. API a specified set protocols data standards establish ground rules which information system directly communicates another. Software developers seamlessly connect program another computer through FHIR API transmit electronic health data. FHIR enables exchange many different health data types such clinical information, demographics, billing claims data. special relevance, complementary specification, Substitutable Medical Applications, Reusable Technologies SMART) FHIR, enables third party applications apps) access data EHR systems approved purposes, including research. FHIR also specifies of specific coding systems required interoperability health data. 1] Section 4002(D)(iv) the 21st Century Cures Act (P.L. 114 – 255) 2] https://www.federalregister.gov/documents/2019/03/04/2019-02224/21st-cen... 3] https://www.federalregister.gov/documents/2019/03/04/2019-02200/medicare... 4] https://www.healthit.gov/topic/certification-ehrs/2015-edition 5] https://chpl.healthit.gov/#/search 6] https://bluebutton.cms.gov/ 7] http://www.hl7.org/about/davinci/ 8] https://transceleratebiopharmainc.com/esource-connectathon-challenge-recap/ 9] https://www.healthleadersmedia.com/innovation/ochsner-and-pfizer-constru... 10] https://datascience.nih.gov/news/nih-releases-strategic-plan-data-science 11] https://osp.od.nih.gov/scientific-sharing/nih-data-management-and-sharin... 12] https://www.nlm.nih.gov/pubs/plan/lrp17/NLM_StrategicReport2017_2027.html 13] https://www.force11.org/group/fairgroup/fairprinciples Inquiries Please direct inquiries to: Belinda Seto, PhD Office Data Science Strategy Email: setob@mail.nih.gov data science, data standards
Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional) RFA-NS-18-041 NINDS Aug 02 2018 Mar 13 2020 The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery of promising candidate biomarkers that will facilitate the development of non-opioid therapeutic options for the treatment of pain conditions. The goal of this FOA is to encourage a biomarker discovery process that will result in the development of pain biomarkers that can withstand rigorous clinical and analytical validation. It is hoped that an increased availability of rigorous biomarkers for pain will facilitate the discovery and development of transformational non-opioid therapeutics for pain.

Pages

XLS